Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06442436 · ClinicalTrials.gov registry record · Phase 1
A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
A Phase 1 study of Hepatic Impairment (HI), sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 3
- Study locations
NCT06442436 is a Phase 1 study of Hepatic Impairment (HI) that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 32 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT06442436, a Phase 1 study of Hepatic Impairment (HI), is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabrutinib.
Conditions Studied
Interventions
- DRUG Nemtabrutinib
Study Locations (3)
Florida
- Clinical Pharmacology of Miami ( Site 0003) - Miami
- Orlando Clinical Research Center ( Site 0001) - Orlando
Texas
- Texas Liver Institute ( Site 0002) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2026-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06442436
The ClinicalTrials.gov registry entry for NCT06442436 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatic Impairment (HI) appearing as the primary indexed condition, and to 1 intervention - of which Nemtabrutinib is the first listed.
NCT06442436 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06442436 about?
NCT06442436 is a clinical study titled "A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)". The purpose of this study is to compare the plasma pharmacokinetics (PK) of nemtabrutinib (MK-1026) following a single oral dose of nemtabrutinib in participants with moderate hepatic impairment to that of healthy matched control participants and to evaluate the safety and tolerability of nemtabruti...
What is the current status of trial NCT06442436?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-07-24. Estimated completion is 2026-09-14.
What conditions does trial NCT06442436 study?
This clinical trial studies the following conditions: Hepatic Impairment (HI).
What interventions are being tested in trial NCT06442436?
The interventions under investigation include: Nemtabrutinib (DRUG).
Who is sponsoring clinical trial NCT06442436?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06442436 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment (HI)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.